Treatment options for visceral leishmaniasis
@article{denBoer2006TreatmentOF, title={Treatment options for visceral leishmaniasis}, author={Margriet den Boer and Robert N. Davidson}, journal={Expert Review of Anti-infective Therapy}, year={2006}, volume={4}, pages={187 - 197} }
This review summarizes the current developments in therapy for visceral leishmaniasis. With the recent introduction of new drugs, the main limits in reducing deaths from visceral leishmaniasis are difficulty in diagnosis in the field and health inequality – patients lack of access to treatment. No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic…
51 Citations
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
- MedicineNature Reviews Microbiology
- 2007
Millefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphoteric in B as the preferred treatments in some regions, but in other areas these drugs are still being evaluated in both mono- and combination therapies.
Current diagnosis and treatment of visceral
- Medicine
- 2010
This article critically addresses the currently available diagnostic and treatment regimens for the control of VL and recommends combination therapy to increase treatment efficacy and prevent the development of resistance.
Current diagnosis and treatment of visceral leishmaniasis
- MedicineExpert review of anti-infective therapy
- 2010
This article critically addresses the currently available diagnostic and treatment regimens for the control of VL and offers more choices for monotherapy and combination therapy for VL.
Drug regimens for visceral leishmaniasis in Mediterranean countries
- MedicineTropical medicine & international health : TM & IH
- 2008
It is shown that antimony resistance is not an emerging problem in the Mediterranean, and VL is now treated differently in the region, basically through three approaches: in Northern Africa and in part of the Middle East, pentavalent antimony is still the mainstay for therapy, with no alternative drug options for treating relapses.
Therapy of vector-borne protozoan infections in nonendemic settings
- MedicineExpert review of anti-infective therapy
- 2011
Progress in the management of leishmaniasis and trypanosomiasis has also been substantial and includes introduction of new drugs into clinical practice, combinations of existing drugs, or new laboratory tools for treatment monitoring.
Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases
- MedicineTropical medicine & international health : TM & IH
- 2009
Large trials are recommended to investigate the efficacy of pentamidine over other agents in preventing relapse of VL in the immunocompromised patient.
Visceral leishmaniasis after renal transplantation: report of 4 cases in northeastern Brazil
- MedicineTransplant infectious disease : an official journal of the Transplantation Society
- 2008
Visceral leishmaniasis is a well recognized opportunistic infection in immunosuppressed patients, which may cause febrile illness in transplanted patients living in endemic areas.
Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo
- Medicine, BiologyInternational journal for parasitology. Drugs and drug resistance
- 2020
Leishmanicidal activity of Artemisinin against cutaneous Leishmaniasis, in Vitro
- MedicineJournal of Biotechnology Research Center
- 2019
The findings approved the leishmanicidal efficacy of Artemisinin against the of L. tropica and can be further studied to screen its effectiveness in vivo for exploring a safer herbal drug for treatment of cutaneous leish maniasis.
References
SHOWING 1-10 OF 113 REFERENCES
Visceral Leishmaniasis Treatment, Italy
- MedicineEmerging infectious diseases
- 2003
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy in the past 12 years, a response to both disease reemergence and increasing antimonial failure.
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis
- MedicineExpert review of anti-infective therapy
- 2004
Renewed interest in visceral leishmaniasis and numerous successful treatment trials have combined to turn a therapeutic corner in the past 5 years, yielding new alternatives to conventional pentavalent antimony.
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
- MedicineClinical infectious diseases : an official publication of the Infectious Diseases Society of America
- 2004
Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.
Advances in the treatment of leishmaniasis
- MedicineCurrent opinion in infectious diseases
- 2002
Generic stibogluconate enables the cost effective treatment of all forms of leishmaniasis as it remains the most important antileishmanial drug in most parts of the world.
Clinical status of agents being developed for leishmaniasis
- MedicineExpert opinion on investigational drugs
- 2005
The most likely replacements for present therapy are oral miltefosine for many of the visceral and cutaneous syndromes, intramuscular paromomycin for visceral disease and topical parommycin for some forms of cutaneous disease.
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
- MedicineThe Lancet. Infectious diseases
- 2005
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
- MedicineThe Lancet. Infectious diseases
- 2002
HIV and the transmission of Leishmania
- Medicine, BiologyAnnals of tropical medicine and parasitology
- 2003
The co-infection of Leishmania/HIV has led not only to marked increases in the sandfly transmission of the parasites from immunodepressed individuals directly to other humans but also, probably, to artificial transmission between immunODepressed intravenous-drug users, as the result of needle sharing.
Kala-azar--progress against a neglected disease.
- MedicineThe New England journal of medicine
- 2002
The report by Sundar and colleagues in this issue of the Journal 1 offers a current perspective on kala-azar and recent advances in treatment and prevention.
Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
- MedicineClinical infectious diseases : an official publication of the Infectious Diseases Society of America
- 2003
Single-dose L-AmB (7.5 mg/kg) treatment is safe and effective, and it may be used for the mass treatment of VL in India.